University of Florida Center for Movement Disorders and Neurorestoration
Gainesville, Florida, 32607, United States
NCT Number: NCT02318927
The study objective is to explore Deep Brain Stimulation (DBS) in two specific brain regions (Globus Pallidum, or GPI, plus the pedunculopontine nucleus, or PPN) for on medication freezing of gait (FoG) in Parkinsons Disease (PD). Hopefully, information gathered from these two brain regions after surgery will allow for the development of a personalized DBS system to address FoG. The primary outcome will be a comparison of the pre-operative number of FoG episodes in the laboratory during the FoG battery versus those 6 months post-DBS at the optimized device settings.
Looking for future studies?
Notify Me30 year–75 year
All sexes
Interventional
Not applicable
Gainesville, Florida, 32607, United States
As a participant in the study you will have the following procedure performed:
A series of questions by interview, questionnaires, and checklists will be collected. In addition, basic information (such as age, sex, race) and psychiatric, medical, and family history, physical and neurological exam that will include measuring vital signs (heart rate and blood pressure). There will be a "Falls Diary' to complete (an account of falling incidents and the details). Specific testing will be done to evaluate the gait and balance which will be repeated throughout the study. A psychiatric evaluation of mood and emotion will be performed including a detailed psychological testing, consisting of perception, learning, and memory. These psychological assessments will be repeated at every study visit. An MRI and a CT scan will be performed to make sure of the exact location of the DBS implant. The study will end in 24 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
Time frame: Change from Baseline to 6 Months
Time frame: Change from Baseline to 24 Months
The DSMB will review all adverse events (AE's) in real time. The device related AE definition will include both therapy and procedure related AE's. The Data Safety Monitoring Board (DSMB) will evaluate the study at least every 6 months and have the power to terminate the study for safety reasons.
Time frame: Change from Baseline to 6 Months
Time frame: Change from Baseline to 6 Months
Time frame: Change from Baseline to 6 Months
Time frame: Change from Baseline to 6 Months
Time frame: Change from Screening to 6 Months
Time frame: Change from Baseline to 6 Months
Time frame: Change from Screening to 6 Months
Time frame: Change from Screening to 6 Months
University of Florida
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02126475
Basal Ganglia Diseases, Brain Diseases
Paris, France
View Trial DetailsNCT02676804
Basal Ganglia Diseases, Behavior
Charlottesville, Virginia, United States
View Trial DetailsNCT02092181
Basal Ganglia Diseases, Brain Diseases
Kirkland, Washington, United States
View Trial DetailsNCT01360229
Basal Ganglia Diseases, Brain Diseases
Aurora, Colorado, United States
View Trial Details